These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Genomic case report of a low grade bladder tumor metastasis to lung. Van Every MJ; Dancik G; Paramesh V; Gurda GT; Meier DR; Cash SE; Richmond CS; Guin S BMC Urol; 2018 Sep; 18(1):74. PubMed ID: 30176882 [TBL] [Abstract][Full Text] [Related]
9. Expression of epidermal growth factor receptor in urinary bladder cancer metastases. Bue P; Wester K; Sjöström A; Holmberg A; Nilsson S; Carlsson J; Westlin JE; Busch C; Malmström PU Int J Cancer; 1998 Apr; 76(2):189-93. PubMed ID: 9537579 [TBL] [Abstract][Full Text] [Related]
10. Tumor behavior in transitional cell carcinoma of the bladder in relation to chromosomal markers and histopathology. Babu VR; Lutz MD; Miles BJ; Farah RN; Weiss L; Van Dyke DL Cancer Res; 1987 Dec; 47(24 Pt 1):6800-5. PubMed ID: 3479251 [TBL] [Abstract][Full Text] [Related]
11. Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification. Palma N; Morris JC; Ali SM; Ross JS; Pal SK Eur Urol; 2015 Jul; 68(1):168-70. PubMed ID: 25766722 [No Abstract] [Full Text] [Related]
12. Flow cytometric analysis of deparaffinized nuclei in urinary bladder carcinoma. Comparison with cytogenetic analysis. Coon JS; Schwartz D; Summers JL; Miller AW; Weinstein RS Cancer; 1986 Apr; 57(8):1594-601. PubMed ID: 3948130 [TBL] [Abstract][Full Text] [Related]
13. Serial cytogenetic analysis in a patient with pseudodiploid bladder cancer. Kovacs G J Cancer Res Clin Oncol; 1985; 110(3):249-51. PubMed ID: 4077924 [TBL] [Abstract][Full Text] [Related]
14. Bladder carcinoma: understanding advanced and metastatic disease with potential molecular therapeutic targets. Ahmed HU; Arya M; Patel HR Expert Rev Anticancer Ther; 2005 Dec; 5(6):1011-22. PubMed ID: 16336092 [TBL] [Abstract][Full Text] [Related]
15. The importance of marker chromosomes in superficial transitional cell carcinoma of the bladder: 50 patients followed up to 17 years. Falor WH; Ward-Skinner RM J Urol; 1988 May; 139(5):929-32. PubMed ID: 3163022 [TBL] [Abstract][Full Text] [Related]
16. Nonrandom chromosomal changes in transitional cell carcinoma of the bladder. Gibas Z; Prout GR; Connolly JG; Pontes JE; Sandberg AA Cancer Res; 1984 Mar; 44(3):1257-64. PubMed ID: 6692407 [TBL] [Abstract][Full Text] [Related]
17. Genetic alterations in primary bladder cancers and their metastases. Hovey RM; Chu L; Balazs M; DeVries S; Moore D; Sauter G; Carroll PR; Waldman FM Cancer Res; 1998 Aug; 58(16):3555-60. PubMed ID: 9721860 [TBL] [Abstract][Full Text] [Related]
19. Commentary on genetic prognostic markers for transitional cell carcinoma of the bladder: from microscopes to molecules. Theodorescu D J Urol; 1996 Jan; 155(1):2. PubMed ID: 7490833 [No Abstract] [Full Text] [Related]
20. Is chromosome 9 loss a marker of disease recurrence in transitional cell carcinoma of the urinary bladder? Bartlett JM; Watters AD; Ballantyne SA; Going JJ; Grigor KM; Cooke TG Br J Cancer; 1998 Jun; 77(12):2193-8. PubMed ID: 9649132 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]